Scott Whitt·April 28, 2021

How to Buy a Clinical Trials Firm & Grow It to $3m

Scott Whitt, a 56-year-old former Deloitte consulting partner and healthcare executive, acquired Triad Clinical Trials in Greensboro, North Carolina in 2015 for approximately $2m (plus ~$500k for the building and equipment), financing the deal through a ROBS structure combining personal savings, IRA rollovers into a C-corp, and an SBA loan. The business — a clinical research site that recruits patients for pharmaceutical trials — was generating ~$850k in revenue with 70% margins but was operationally chaotic: manual payroll, no systems, underqualified staff, and a misrepresented backlog that nearly sank the new ownership. Scott drew on his 30 years of healthcare industry relationships and consulting turnaround experience to rebuild the pipeline through aggressive business development, replace virtually the entire staff with experienced clinical research professionals, and invest in technology and patient recruitment infrastructure. By the time of the interview the business had tripled revenue to ~$3m, and Triad had become one of the top-enrolling clinical research sites in the country, leveraging its track record to negotiate significantly higher sponsor budgets and walk away from underpriced studies. Scott runs the business largely in a business-development and deal-negotiation role alongside his wife, and is exploring geographic expansion and potential roll-up opportunities.

Deal facts

purchase price: ~$2m for the business + ~$500k for building/equipment (all-in ~$2.5m)
sde ebitda: ~70% margins on ~$850k revenue
revenue: $850k at acquisition; ~$3m at time of interview
financing structure: Personal savings + IRA rollover into C-corp + SBA loan + personal guarantees (lien on home equity and ~$1m in investments)
notes: Used a ROBS-style structure via Monty Walker / Walker Advisory to roll IRAs into the acquisition entity. Withheld final payments to seller (~$200-300k less than seller anticipated) due to misrepresented backlog and cash collection cycles.

Why this business

Scott had 30+ years in healthcare and knew the clinical trials market well from his time at Quintiles (the world's largest CRO). He saw a business with 70% margins, a strong brand, and massive unmet demand for clinical trial site capacity — and believed the operational train wreck was entirely fixable with systems, better staff, and his consulting background. He also wanted to stop traveling constantly, have autonomy, and build something with his wife.

What's working

Upgraded staff quality — hired experienced clinical research nurses and coordinators who are genuinely passionate about research; competitive on work-life balance over raw compensation
Added strong physician investigators whose credentials impress sponsors (e.g., a urologist with 25 years of experience)
Built a full-time patient recruitment function — one dedicated recruiter working phones, Facebook ads, Google ads; became top-enrolling site in the country on 5 of the last 18 months' studies
Pricing power through performance — once they demonstrated top enrollment, negotiated higher overhead rates (20% up to 35%) and walked away from low-budget sponsors; major pharma (Novartis, AstraZeneca) willing to pay premium for reliable enrollment speed
Invested in systems and technology up front, creating operational efficiency the previous owner never pursued
Strong legacy brand name — still generating inbound calls from sponsors who worked with the site 7-8 years earlier
Quintiles network and reputation gave credibility with major CRO clients who are now among their biggest sponsors

What's hard

Backlog was wildly overstated at acquisition — estimated $1.5m in booked work turned out to be ~$500k, nearly threatening the business's viability in the first months
Cash collection cycle was misrepresented: seller implied ~45 days, reality was 120-140 days; created severe cash flow stress
Previous owner had been running everything manually (hand-drawn spreadsheets, manual payroll with IRS withholding tables) — no real systems, no reliable records
100% staff turnover in the first 3-4 months; most inherited employees were underqualified and underpaid, and several had already accepted other jobs before the deal closed
Had to withhold final seller payments and engage a litigator, leading to contentious negotiations with the seller
Insufficient working capital built into the deal; banks were unsympathetic post-close
Due diligence was limited — seller would not allow extended on-site review; buyer was also emotionally motivated and somewhat myopic about the risks
Pipeline presented by the seller was 'erotic fiction' — included studies that were essentially impossible to deliver

Notable quotes

It was a train wreck that generated 70 margins and I thought with 70 I got some time to figure things out.

Pipeline is a work of erotic fiction most of the time — it's and unless you really know these companies you know you're going to get this you feel like you'll enroll at those studies it's not really shouldn't be.

I probably looked at it a little myopically, probably wildly optimistic about what was really there because I wanted this business to happen. My emotions got out ahead of my logic on that.

Based on the quality of my staff based on our results I just negotiate much more aggressively and I walk away from studies that are clients who are not... it's pretty clear when they send you the budget — 'well we're looking to do this quickly and inexpensively' — I said yeah go push your development costs on somebody else.